DiaMedica Therapeutics Inc.

Moderna Inc. launched the much anticipated, largest-ever drug developer initial public offering raising $604.3m on Dec. 6, but the IPO landed with a thud, reflecting ongoing unease in the US stock ma

Recent biopharmaceutical initial public offerings show that the IPO boom is not limited to the US, and illustrate the challenges of going public in any market. US stock values have plummeted in recent

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer